{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.53","upperLimit":"2.13","value":"24"},{"groupId":"OG001","lowerLimit":"0.53","upperLimit":"2.13","value":"23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"Serum Creatinine was considered to be significantly increased if there was an increase of 0.5 mg/dL or more or a doubling of the baseline serum creatinine value.","groups":[{"description":"Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks.","id":"OG000","title":"15 - Minute Infusion"},{"description":"Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.","id":"OG001","title":"30 - Minute Infusion"}],"paramType":"NUMBER","populationDescription":"Safety Population; enrolled patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Baseline and 24 Months","title":"The Number of Participants With a Significant Increase in Serum Creatinine at 24 Months","type":"SECONDARY","unitOfMeasure":"Participants"}